GlassScriptPhysician profile
Melissa A Iler
NPI 1184083198
$5,224.67
in general payments reported to CMS, 2019-2025
30 companies · $1,075 in 2025
The $1,075 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,428 · 2022: $891 · 2023: $837 · 2024: $993 · 2025: $1,075.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,904.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $860.05 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $852.67 | 2021-2025 | |
| Novo Nordisk INC | $665.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $580.01 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $287.65 | 2021-2025 | Otezla, Repatha, Repatha |
| Pfizer INC. | $237.64 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $192.25 | 2021-2024 | Verquvo, Belsomra, Steglatro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.31 | 2021-2025 | Jardiance, Tradjenta, Synjardy |
| Sanofi-Aventis U.S. LLC | $177.65 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $123.90 | 2021-2022 | |
| Abbott Laboratories | $119.80 | 2021-2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $110.38 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $91.33 | 2022-2024 | |
| Kowa Pharmaceuticals America, INC. | $84.39 | 2021-2025 | Livalo, Seglentis, Zoryve |
| Pharming Healthcare, INC. | $79.43 | 2022-2025 | Ruconest |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $78.40 | 2021-2024 | Takhzyro |
| Glaxosmithkline, LLC. | $74.60 | 2021-2023 | Shingrix |
| Corium, LLC | $51.28 | 2021-2023 | Azstarys |
| Biohaven Pharmaceutical Holding Company LTD. | $45.21 | 2022 | |
| Esperion Therapeutics, INC. | $44.71 | 2023-2025 | Nexletol |
| Eisai INC. | $44.68 | 2021 | |
| Genentech USA, INC. | $37.12 | 2021 | |
| Vbi Vaccine (Delaware) INC. | $36.31 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $35.07 | 2021 | |
| Biocryst US Sales Co., LLC | $29.00 | 2021 | |
| Dexcom, INC. | $28.55 | 2025 | Dexcom G6 Transmitter |
| Halozyme INC | $25.21 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.90 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.52 | 2023 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $13.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Iler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.